(Q46959422)

26 December 2017

title

Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy (English)

1 reference

26 December 2017

0 references

1 reference

O Schnell

1

1 reference

26 December 2017

G Mertes

series ordinal

2

1 reference

26 December 2017

E Standl

series ordinal

3

1 reference

26 December 2017

Acarbose-Insulin Combination Study Group

series ordinal

4

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Diabetes, Obesity and Metabolism

published in

1 reference

26 December 2017

volume

9

1 reference

26 December 2017

issue

6

1 reference

26 December 2017

page(s)

853-858

1 reference

26 December 2017

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Effect of acarbose on insulin sensitivity in elderly patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Effects of combination of insulin and acarbose compared with insulin and gliclazide in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

Recent findings concerning thiazolidinediones in the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2006.00666.X

10.1111/J.1463-1326.2006.00666.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17924867

1 reference

26 December 2017